{
    "ticker": "IVA",
    "name": "Inventiva S.A.",
    "description": "Inventiva S.A. is a biopharmaceutical company dedicated to the development of innovative therapies for patients with severe diseases. Founded in 2011 and headquartered in Daillens, Switzerland, the company focuses on addressing unmet medical needs, particularly in the fields of liver diseases and rare diseases. Inventiva\u2019s lead product candidate, lanifibranor, is a novel therapy currently in development for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease that can lead to cirrhosis and liver cancer. The company employs a strong research and development strategy, leveraging its proprietary technology platform to discover and develop small molecule drugs. In addition to lanifibranor, Inventiva is also exploring treatments for systemic sclerosis and other fibrotic conditions. With a commitment to scientific excellence and patient-centric solutions, Inventiva seeks to transform the landscape of chronic diseases and improve the quality of life for patients worldwide. The company collaborates with various academic institutions and industry partners to enhance its research capabilities and expedite the development of its therapeutic candidates.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Daillens, Switzerland",
    "founded": "2011",
    "website": "https://www.inventivapharma.com",
    "ceo": "Fr\u00e9d\u00e9ric Cren",
    "social_media": {
        "twitter": "https://twitter.com/InventivaPharma",
        "linkedin": "https://www.linkedin.com/company/inventiva/"
    },
    "investor_relations": "https://www.inventivapharma.com/investors",
    "key_executives": [
        {
            "name": "Fr\u00e9d\u00e9ric Cren",
            "position": "CEO"
        },
        {
            "name": "M\u00e9lanie Roussel",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Lanifibranor"
            ]
        }
    ],
    "seo": {
        "meta_title": "Inventiva S.A. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Inventiva S.A., a biopharmaceutical company focused on innovative therapies for liver and rare diseases. Learn about their research and product pipeline.",
        "keywords": [
            "Inventiva",
            "Biopharmaceuticals",
            "Lanifibranor",
            "NASH",
            "Liver Disease",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Inventiva known for?",
            "answer": "Inventiva is known for its development of innovative therapies for liver diseases and rare diseases, particularly its lead candidate lanifibranor for NASH."
        },
        {
            "question": "Who is the CEO of Inventiva?",
            "answer": "Fr\u00e9d\u00e9ric Cren is the CEO of Inventiva S.A."
        },
        {
            "question": "Where is Inventiva headquartered?",
            "answer": "Inventiva is headquartered in Daillens, Switzerland."
        },
        {
            "question": "What are Inventiva's main products?",
            "answer": "Inventiva's main product candidate is lanifibranor, designed for the treatment of NASH."
        },
        {
            "question": "When was Inventiva founded?",
            "answer": "Inventiva was founded in 2011."
        }
    ],
    "competitors": [
        "GILD",
        "MRNA",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "BMY",
        "JNJ"
    ]
}